Ethopropazine

CHEMBL1206 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
312.5 g/mol
LogP
4.8
Phase
4

This phenothiazine medication blocks certain receptors in the nervous system and has anticholinergic properties that help relieve muscle stiffness and tremor in Parkinson's disease. It also has some antihistamine activity.

分子量

312.5000 g/mol

LogP

4.80

TPSA

31.80 Ų

Lipinski 五规则

符合

作用机制

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21

InChI

InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3

Molecular Formula

C19H24N2S

HBD / HBA

- / 3

可旋转键数

5

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This phenothiazine medication blocks certain receptors in the nervous system and has anticholinergic properties that help relieve muscle stiffness and tremor in Parkinson's disease. It also has some antihistamine activity.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Ethopropazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1206. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3290. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.